Hypofractionated Whole-Breast Irradiation Focus on Coronary Arteries and Cardiac Toxicity-A Narrative Review

Camil Ciprian Mireştean; Roxana Irina Iancu; Dragoş Petru Teodor Iancu

doi:10.3389/fonc.2022.862819

Hypofractionated Whole-Breast Irradiation Focus on Coronary Arteries and Cardiac Toxicity-A Narrative Review

Front Oncol. 2022 Apr 7:12:862819. doi: 10.3389/fonc.2022.862819. eCollection 2022.

Authors

Camil Ciprian Mireştean^{1

2}, Roxana Irina Iancu^{3

4}, Dragoş Petru Teodor Iancu^{5

6}

Affiliations

¹ Department of Medical Oncology and Radiotherapy, University of Medicine and Pharmacy Craiova, Craiova, Romania.
² Department of Surgery, Railways Clinical Hospital, Iasi, Romania.
³ Oral Pathology Department, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
⁴ Department of Clinical Laboratory, St. Spiridon Emergency Hospital, Iaşi, Romania.
⁵ Department of Medical Oncology and Radiotherapy Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
⁶ Department of Radiation Oncology, Regional Institute of Oncology, Iasi, Romania.

Abstract

Breast cancer is the most common cancer among women worldwide, which is often treated with radiotherapy. Whole breast irradiation (WBI) is one of the most common types of irradiation. Hypo-fractionated WBI (HF-WBI) reduces the treatment time from 5 to 3 weeks. Recent radiobiological and clinical evidence recommended the use of HF-WBI regardless of the age or stage of disease, and it is proven that hypo-fractionation is non-inferior to conventional fractionation regimen irradiation. However, some studies report an increased incidence of heart-related deaths in the case of breast irradiation by hypo-fractionation, especially in patients with pre-existing cardiac risk factors at the time of treatment. Due to the new technical possibilities of radiotherapy techniques, HF-WBI can reduce the risk of cardiac toxicity by controlling the doses received both by the heart and by the anatomical structures of the heart. The radiobiological "double trouble", in particular "treble trouble", for hypo-fractionated regimen scan be avoided by improving the methods of heart sparing based on image-guided irradiation (IGRT) and by using respiration control techniques so that late cardiac toxicity is expected to be limited. However, long-term follow-up of patients treated with HF-WBI with modern radiotherapy techniques is necessary considering the progress of systemic therapy, which is associated with long-term survival, and also the cardiac toxicity of new oncological treatments. The still unknown effects of small doses spread in large volumes on lung tissue may increase the risk of second malignancy, but they can also be indirectly involved in the later development of a heart disease. It is also necessary to develop multivariable radiobiological models that include histological, molecular, clinical, and therapeutic parameters to identify risk groups and dosimetric tolerance in order to limit the incidence of late cardiac events. MR-LINAC will be able to offer a new standard for reducing cardiac toxicity in the future, especially in neoadjuvant settings for small tumors.

Keywords: HF-WBI; breast; cardiac toxicity; chemotherapy; coronary arteries; hypo-fractionated radiotherapy.

Publication types

Review